OLIG2 and myeloid sarcoma: Mice treated with afatinib had increased numbers of Olig2+ oligodendrocytes, which previously had been described to enhance remyelination in active and chronic MS lesions (17) (Figure 6G and Supplemental Figure 7, E and F).